Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change (NCT03191149)

🧪 Interventions in This Study

• Osimertinib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (344 Sites)

Showing the first 25 of 344 sites.

• Anchorage Associates in Radiation Medicine — Anchorage, Alaska
• Anchorage Radiation Therapy Center — Anchorage, Alaska
• Alaska Breast Care and Surgery LLC — Anchorage, Alaska
• Alaska Oncology and Hematology LLC — Anchorage, Alaska
• Alaska Women's Cancer Care — Anchorage, Alaska
• Anchorage Oncology Centre — Anchorage, Alaska
• Katmai Oncology Group — Anchorage, Alaska
• Providence Alaska Medical Center — Anchorage, Alaska
• Fairbanks Memorial Hospital — Fairbanks, Alaska
• Mercy Hospital Fort Smith — Fort Smith, Arkansas
• CARTI Cancer Center — Little Rock, Arkansas
• Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
• MedStar Georgetown University Hospital — Washington D.C., District of Columbia
• Holy Cross Hospital — Fort Lauderdale, Florida
• Emory University Hospital Midtown — Atlanta, Georgia
• Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
• Emory Saint Joseph's Hospital — Atlanta, Georgia
• Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
• Saint Luke's Cancer Institute - Boise — Boise, Idaho
• Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
• Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
• Walter Knox Memorial Hospital — Emmett, Idaho
• Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho
• Idaho Urologic Institute-Meridian — Meridian, Idaho
• Saint Luke's Cancer Institute - Meridian — Meridian, Idaho

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Lung Non-Small Cell Carcinoma

• Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer — Birmingham, Alabama
• Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors — Orange, California
• Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) — Birmingham, Alabama
• Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer — Duarte, California
• CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer — Buffalo, New York
• Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer — Duarte, California

Explore by condition: All Advanced Lung Non-Small Cell Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.